{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:34:09Z","timestamp":1762544049443,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In BRAF-mutated high-risk melanoma, targeted therapy (BRAF\/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF\/MEK inhibitors and CPI immunotherapies, there is interest in evaluating the activity of 2L adjuvant targeted therapy in decreasing the risk of subsequent recurrence after repeat resection following relapse on\/after 1L adjuvant CPI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>This was a retrospective review of BRAF V600-mutated resected stage III\/IV melanoma patients in the United States, Australia, and The Netherlands who received 1L adjuvant CPI immunotherapy, relapsed locoregionally\/distantly, were again resected to no evidence of disease, and received dabrafenib\/trametinib (dab\/tram) as 2L adjuvant therapy. The primary endpoint was relapse-free survival (RFS) from initiation of 2L adjuvant dab\/tram (RFS-2), analyzed via Kaplan-Meier methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-eight patients were included (median age 50 years, 63% male, 87% stage III, median follow-up 19 months from 2L dab\/tram initiation). Median dab\/tram duration was 10.1 months (range: 1 day\u201322.7 months), with half discontinuing due to progression or adverse events. Median (95% CI) RFS-2 was 18.9 (14.9\u201328.1) months, with 91%, 81%, and 58% remaining relapse-free at 6, 12, and 18 months, respectively. Most patients remained distant metastasis-free at 6, 12, and 18 months (97%, 85%, and 71%, respectively). Two patients were deceased at the last follow-up, with 97% alive at 18 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Over 80% of patients remained relapse- and metastasis-free at 12 months after 2L dab\/tram initiation, with only 2 deaths observed. Dab\/tram appears to have activity in the 2L adjuvant setting, although more follow-up is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae289","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:31:51Z","timestamp":1732033911000},"source":"Crossref","is-referenced-by-count":1,"title":["Relapse-free survival with adjuvant dabrafenib\/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III\/IV melanoma"],"prefix":"10.1093","volume":"30","author":[{"given":"Jeffrey","family":"Weber","sequence":"first","affiliation":[{"name":"Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Grossman School of Medicine , NYU Langone, New York, NY\u00a010016 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqas","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman School of Medicine , NYU Langone, New York, NY 10016 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetomir N","family":"Markovic","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center , Rochester, MN\u00a055905 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April K S","family":"Salama","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Duke University School of Medicine , Durham, NC\u00a027710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderjit","family":"Mehmi","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute , Cedars Sinai, Los Angeles, CA 90025 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Center for Melanoma , Massachusetts General Hospital, Boston, MA 02114 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana G","family":"Najjar","sequence":"additional","affiliation":[{"name":"Clinical and Translational Research Center, UPMC Hillman Cancer Center , Pittsburgh, PA 15232 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C J","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Melanoma Surgical Oncology, Melanoma Institute Australia, Wollstonecraft , Sydney, NSW 2065 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney, Camperdown , Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Department of Melanoma and Soft Tissue Sarcoma, Division of Surgical Oncology, Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek , 1066 CX Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M","family":"Menzies","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of Sydney, Camperdown , Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Medical Oncology, Melanoma Institute Australia , Wollstonecraft, Sydney, NSW 2065 ,","place":["Australia"]},{"name":"Medical Oncology, Royal North Shore Hospital, Northern Sydney Cancer Centre , St Leonards, NSW\u00a02065 ,","place":["Australia"]},{"name":"Department of Cancer Medicine , Mater Hospital, North Sydney, NSW\u00a02060 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V","family":"Long","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of Sydney, Camperdown , Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Medical Oncology, Melanoma Institute Australia , Wollstonecraft, Sydney, NSW 2065 ,","place":["Australia"]},{"name":"Medical Oncology, Royal North Shore Hospital, Northern Sydney Cancer Centre , St Leonards, NSW\u00a02065 ,","place":["Australia"]},{"name":"Medical Oncology , Mater Hospital, North Sydney, NSW 2060 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia M","family":"Taylor","sequence":"additional","affiliation":[{"name":"Medical Oncology, Melanoma Institute Australia , Wollstonecraft, Sydney, NSW 2065 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Haanen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek , 1066 CX Amsterdam ,","place":["The Netherlands"]},{"name":"Medical Oncology (Service d\u2019oncologie m\u00e9dicale), Centre Hospitalier Universitaire Vaudois (CHUV) , 1005 Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisanne P","family":"Zijlker","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek , 1066 CX Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith L","family":"Davis","sequence":"additional","affiliation":[{"name":"Medical Oncology, Royal North Shore Hospital, Northern Sydney Cancer Centre , St Leonards, NSW\u00a02065 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-2692","authenticated-orcid":false,"given":"Siddharth","family":"Karanth","sequence":"additional","affiliation":[{"name":"Real-World Data and Analytics, RTI Health Solutions , Research Triangle Park, NC 27709 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Norton","sequence":"additional","affiliation":[{"name":"Melanoma US Medical Team, Novartis Pharmaceuticals Corporation , East Hanover, NJ 07936 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Connolly","sequence":"additional","affiliation":[{"name":"Real World Evidence Solutions, CONEXTS, Novartis Ireland Ltd. , Dublin 4, D04 NN12 , \u00a0","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"2025033007272455200_CIT0001","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"2025033007272455200_CIT0002","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"2025033007272455200_CIT0003","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"2025033007272455200_CIT0004","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"2025033007272455200_CIT0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s11912-022-01288-y","article-title":"Treatment approaches for melanomas that relapse after adjuvant or neoadjuvant therapy","volume":"24","author":"Ng","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2025033007272455200_CIT0006","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"key":"2025033007272455200_CIT0007","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41416-020-01121-y","article-title":"Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis","volume":"124","author":"Bhave","year":"2021","journal-title":"Br J Cancer"},{"key":"2025033007272455200_CIT0008","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1200\/jco.2021.39.15_suppl.9525","article-title":"Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): primary results of COMBI-APlus","volume":"39","author":"Atkinson","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025033007272455200_CIT0009","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"2025033007272455200_CIT0010","doi-asserted-by":"publisher","first-page":"113561","DOI":"10.1016\/j.ejca.2024.113561","article-title":"Efficacy and safety of \u201cSecond Adjuvant\u201d therapy with BRAF\/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy","volume":"199","author":"Taylor","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae289\/60750759\/oyae289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae289\/60750759\/oyae289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:13:22Z","timestamp":1743452002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae289\/7904715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae289","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,19]]},"article-number":"oyae289"}}